ReviewCurrent opinion in biotechnology2014
Designer microbes for biosynthesis.
Review in Current opinion in biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Engineering bacterial cell morphology for the design of robust cell factories.Biochemistry and biophysics reports · 2025Review
- Enhancement of iminosugar production, 1-deoxynojirimycin and 1-deoxymannojirimycin, in recombinantFood science and biotechnology · 2025Article
- Controlling evolutionary dynamics to optimize microbial bioremediation.Evolutionary applications · 2020Article
- Genome Mining as New Challenge in Natural Products Discovery.Marine drugs · 2020Review
- Regulation of Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κβ) in Inflammatory Bowel Diseases.Frontiers in pediatrics · 2018Review
- In vivo plug-and-play: a modular multi-enzyme single-cell catalyst for the asymmetric amination of ketoacids and ketones.Microbial cell factories · 2017Article
- Synthetic Biology of Natural Products.Cold Spring Harbor perspectives in biology · 2016Review
- Cloning, expression and characterization of a novel cold-active and organic solvent-tolerant esterase from Monascus ruber M7.Extremophiles : life under extreme conditions · 2016Article
- Review
- Microbial production strategies and applications of lycopene and other terpenoids.World journal of microbiology & biotechnology · 2016Article
- Engineered biosynthesis of natural products in heterologous hosts.Chemical Society reviews · 2015Review
- Escherichia coli enoyl-acyl carrier protein reductase (FabI) supports efficient operation of a functional reversal of β-oxidation cycle.Applied and environmental microbiology · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Microbes have long been adapted for the biosynthetic production of useful compounds. There is increasing demand for the rapid and cheap microbial production of diverse molecules in an industrial setting. Microbes can now be designed and engineered for a particular biosynthetic purpose, thanks to recent developments in genome sequencing, metabolic engineering, and synthetic biology. Advanced tools exist for the genetic manipulation of microbes to create novel metabolic circuits, making new products accessible. Metabolic processes can be optimized to increase yield and balance pathway flux. Progress is being made towards the design and creation of fully synthetic microbes for biosynthetic purposes. Together, these emerging technologies will facilitate the production of designer microbes for biosynthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.